PL1789041T3 - Pochodne arylopirydyny jako inhibitory 11-beta-HSD1 - Google Patents

Pochodne arylopirydyny jako inhibitory 11-beta-HSD1

Info

Publication number
PL1789041T3
PL1789041T3 PL05776709T PL05776709T PL1789041T3 PL 1789041 T3 PL1789041 T3 PL 1789041T3 PL 05776709 T PL05776709 T PL 05776709T PL 05776709 T PL05776709 T PL 05776709T PL 1789041 T3 PL1789041 T3 PL 1789041T3
Authority
PL
Poland
Prior art keywords
beta
aryl
pyridine derivatives
hsd1 inhibitors
hsd1
Prior art date
Application number
PL05776709T
Other languages
English (en)
Inventor
Kurt Amrein
Daniel Hunziker
Bernd Kuhn
Alexander Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL1789041T3 publication Critical patent/PL1789041T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL05776709T 2004-07-28 2005-07-20 Pochodne arylopirydyny jako inhibitory 11-beta-HSD1 PL1789041T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04103639 2004-07-28
PCT/EP2005/007894 WO2006010546A2 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
EP05776709A EP1789041B1 (en) 2004-07-28 2005-07-20 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors

Publications (1)

Publication Number Publication Date
PL1789041T3 true PL1789041T3 (pl) 2008-11-28

Family

ID=35427898

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05776709T PL1789041T3 (pl) 2004-07-28 2005-07-20 Pochodne arylopirydyny jako inhibitory 11-beta-HSD1

Country Status (26)

Country Link
US (2) US7528159B2 (pl)
EP (1) EP1789041B1 (pl)
JP (1) JP4690402B2 (pl)
KR (1) KR100926842B1 (pl)
CN (1) CN100589803C (pl)
AR (1) AR049739A1 (pl)
AT (1) ATE400271T1 (pl)
AU (1) AU2005266531B2 (pl)
BR (1) BRPI0513864A (pl)
CA (1) CA2574875C (pl)
DE (1) DE602005008079D1 (pl)
DK (1) DK1789041T3 (pl)
ES (1) ES2309789T3 (pl)
HR (1) HRP20080477T3 (pl)
IL (1) IL180481A (pl)
MX (1) MX2007000789A (pl)
MY (1) MY138941A (pl)
NO (1) NO20070458L (pl)
NZ (1) NZ552398A (pl)
PL (1) PL1789041T3 (pl)
PT (1) PT1789041E (pl)
RU (1) RU2374239C2 (pl)
SI (1) SI1789041T1 (pl)
TW (1) TW200608972A (pl)
WO (1) WO2006010546A2 (pl)
ZA (1) ZA200700181B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1789041B1 (en) * 2004-07-28 2008-07-09 F. Hoffmann-Roche AG Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2007092435A2 (en) * 2006-02-07 2007-08-16 Wyeth 11-beta hsd1 inhibitors
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
US8236789B2 (en) 2008-08-29 2012-08-07 Kowa Company, Ltd. 1-adamantyl azetidin-2-one derivatives and drugs containing same
JP5477973B2 (ja) 2008-10-29 2014-04-23 興和株式会社 １，２−ジアゼチジン−３−オン誘導体及びこれを含有する医薬
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
NZ596302A (en) 2009-05-15 2014-01-31 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012124825A1 (en) * 2011-03-16 2012-09-20 Mitsubishi Tanabe Pharma Corporation Sulfonamide compounds having trpm8 antagonistic activity
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
CN104684891A (zh) * 2012-12-10 2015-06-03 弗·哈夫曼-拉罗切有限公司 作为RORc调节剂的苄基磺酰胺衍生物
CN105175323B (zh) * 2015-09-16 2017-12-22 浙江海翔药业股份有限公司 一种制备2‑（4‑乙酰胺基苯磺酰基）胺基吡啶的方法
CA3086668A1 (en) * 2018-02-05 2019-08-08 Universite De Strasbourg Compounds and compositions for the treatment of pain
BR112020018094A2 (pt) 2018-03-08 2020-12-22 Incyte Corporation Compostos de aminopirazina diol como inibidores de pi3k-¿
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
KR102418518B1 (ko) * 2020-08-05 2022-07-07 성균관대학교산학협력단 설퍼 일라이드를 이용한 n-헤테로고리의 선택적 알킬화 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ261095A3 (en) * 1994-10-07 1996-04-17 Sankyo Co Oxime derivatives, process of their preparation, pharmaceutical composition containing thereof and their use
MXPA04004837A (es) * 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
DE60236541D1 (de) 2001-11-22 2010-07-08 Biovitrum Ab Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
US20050272036A1 (en) * 2002-07-27 2005-12-08 Barton Peter J Ketones
EP1789041B1 (en) * 2004-07-28 2008-07-09 F. Hoffmann-Roche AG Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors

Also Published As

Publication number Publication date
CN1988905A (zh) 2007-06-27
KR100926842B1 (ko) 2009-11-13
AU2005266531B2 (en) 2008-11-20
MX2007000789A (es) 2007-03-23
RU2374239C2 (ru) 2009-11-27
HK1105592A1 (zh) 2008-02-22
CA2574875C (en) 2010-09-28
BRPI0513864A (pt) 2008-05-20
US20090149503A1 (en) 2009-06-11
EP1789041A2 (en) 2007-05-30
KR20070026865A (ko) 2007-03-08
PT1789041E (pt) 2008-08-20
CA2574875A1 (en) 2006-02-02
WO2006010546A2 (en) 2006-02-02
AU2005266531A1 (en) 2006-02-02
SI1789041T1 (sl) 2008-10-31
EP1789041B1 (en) 2008-07-09
US8211913B2 (en) 2012-07-03
ZA200700181B (en) 2009-03-25
RU2007107189A (ru) 2008-09-10
JP4690402B2 (ja) 2011-06-01
US7528159B2 (en) 2009-05-05
JP2008508212A (ja) 2008-03-21
HRP20080477T3 (en) 2008-12-31
CN100589803C (zh) 2010-02-17
NO20070458L (no) 2007-01-24
IL180481A (en) 2011-05-31
TW200608972A (en) 2006-03-16
WO2006010546A3 (en) 2006-04-13
US20060025455A1 (en) 2006-02-02
NZ552398A (en) 2010-08-27
DE602005008079D1 (de) 2008-08-21
ATE400271T1 (de) 2008-07-15
IL180481A0 (en) 2007-06-03
MY138941A (en) 2009-08-28
ES2309789T3 (es) 2008-12-16
AR049739A1 (es) 2006-08-30
DK1789041T3 (da) 2008-09-08

Similar Documents

Publication Publication Date Title
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200806148B (en) 2-adamantylurea derivatives as selective 11ß-HSD1 inhibitors
ZA200610771B (en) Quinazolinedolone derivatives as PARP inhibitors
ZA200710951B (en) Piperidinyl-substituted isoquinolone derivatives as Rhokinase inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL179398A0 (en) Dpp-ib inhibitors
ZA200606683B (en) Pyrazolotriazines as kinase inhibitors
TWI369356B (en) Tetrahydropyridoindole derivatives
ZA200610102B (en) Pyrrazolo-pyrimidine derivatives
PL1846394T3 (pl) Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
IL183140A0 (en) Substituted benzoquinolizine derivatives
ZA200703172B (en) Imidazo-benzodiazepine derivatives
IL182739A0 (en) Acylatednonadepsipeptides used as lysobactin derivatives
PT1763517E (pt) Derivados de pirimidina como inibidores 11beta-hsd1
GB0414272D0 (en) OsK1 derivatives
ZA200800672B (en) Introcatechol derivatives as COMT inhibitors
GB0421355D0 (en) Inhibitors
IL179444A0 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
TWI346109B (en) 4-amino-5-cyanopyrimidine derivatives
IL182001A0 (en) 2-acylaminothiazole derivatives
GB0421356D0 (en) Inhibitors
GB0408300D0 (en) Novel inhibitors
GB0422397D0 (en) 3-Cyano-Quinoline derivatives
GB0405905D0 (en) Azaquinazoline derivatives